Rain Therapeuticsm, Inc. announced completion of enrollment in its Phase III MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.
[Rain Therapeutics, Inc.]